Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants

Shujin Wang, Yan Yu, Paul Ryan, Minyan Dang, Cain Clark, Vasileios Kontogi, Jamal Rahmani, Hamed Kord-Varkaneh, Ammar Salehisahlabadi, Andrew S Day, Yong Zhang

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)
16 Downloads (Pure)

Abstract

Although aspirin is commonly used for the prevention of cardiovascular disease, evidence from research has shown that these beneficial effects might extend to hepatocellular carcinoma (HCC). This dose-response analysis was performed to investigate the association between aspirin use and risk of HCC. A systematic search was conducted in MEDLINE/PubMed, SCOPUS, Cochrane, and Web of Science databases from inception up to 29th October 2019. DerSimonian and Laird Random-effects model was used to estimate pooled hazard ratios (HRs) from included studies. Overall, eight studies containing 2,604,319 participants evaluating the association between aspirin use and risk of HCC were uncovered and included in the present meta-analysis. Pooled results of included studies showed a significant reduction in risk of HCC in participants who used aspirin (HR 0.59, 95% CI 0.47-0.75, Pheterogeneity=0.001, I2=90%). In total, 13636 cases of HCC detected during the follow-up period of these studies. Furthermore, linear dose-response model showed an significant inverse association between aspirin dose and risk of HCC (exp (b) = 0.994, p<0.001), while non-linear dose-response analysis revealed an even more robust association (Coef1=-0.008, p1=0.04, Coef2=0.033, p2=0.13). This systematic review and dose-response analysis identified significant inverse relation between aspirin and risk of HCC using both linear and non-linear models.
Original languageEnglish
Article number104585
JournalPharmacological Research
Volume151
Early online date6 Dec 2019
DOIs
Publication statusPublished - Jan 2020

Bibliographical note

NOTICE: this is the author’s version of a work that was accepted for publication in Pharmacological Research. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Pharmacological Research, 151, (2020) DOI: 10.1016/j.phrs.2019.104585

© 2020, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

Keywords

  • Aspirin
  • Hepatocellular carcinoma
  • Liver cancer

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants'. Together they form a unique fingerprint.

Cite this